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Viral Evolution and Cytotoxic T Cell 
Restricted Selection in Acute Infant 
HIV-1 Infection
Miguel A. Garcia-Knight1,2, Jennifer Slyker3, Barbara Lohman Payne4,5, 
Sergei L. Kosakovsky Pond6, Thushan I. de Silva7, Bhavna Chohan3,8,  
Brian Khasimwa8, Dorothy Mbori-Ngacha4, Grace John-Stewart3,5,9,10,  
Sarah L. Rowland-Jones1,* & Joakim Esbjörnsson1,11,*
Antiretroviral therapy-naive HIV-1 infected infants experience poor viral containment and rapid disease 
progression compared to adults. Viral factors (e.g. transmitted cytotoxic T- lymphocyte (CTL) escape 
mutations) or infant factors (e.g. reduced CTL functional capacity) may explain this observation. We 
assessed CTL functionality by analysing selection in CTL-targeted HIV-1 epitopes following perinatal 
infection. HIV-1 gag, pol and nef sequences were generated from a historical repository of longitudinal 
specimens from 19 vertically infected infants. Evolutionary rate and selection were estimated for 
each gene and in CTL-restricted and non-restricted epitopes. Evolutionary rate was higher in nef and 
gag vs. pol, and lower in infants with non-severe immunosuppression vs. severe immunosuppression 
across gag and nef. Selection pressure was stronger in infants with non-severe immunosuppression 
vs. severe immunosuppression across gag. The analysis also showed that infants with non-severe 
immunosuppression had stronger selection in CTL-restricted vs. non-restricted epitopes in gag and nef. 
Evidence of stronger CTL selection was absent in infants with severe immunosuppression. These data 
indicate that infant CTLs can exert selection pressure on gag and nef epitopes in early infection and that 
stronger selection across CTL epitopes is associated with favourable clinical outcomes. These results 
have implications for the development of paediatric HIV-1 vaccines.
Clear differences in the natural history of acute infection exist between adults and infants both clinically and 
with respect to viral population dynamics and the nature of the cytotoxic T cell (CTL) response. Where adults 
typically progress to AIDS over 8–10 years if untreated, infants experience extremely rapid progression, with 
50% of African infants dying before they are 2 years old1,2. Despite the uncontrolled viral replication and high 
mortality rates associated with vertical HIV-1 transmission, a proportion of infants experience delayed clinical 
and immunological progression in the absence of antiretroviral therapy that can persist into childhood and even 
adolescence3. The mediators of infant immunity that contribute to slow progression in paediatric HIV-1 infection 
remain largely unknown.
Acute HIV-1 infection in adults is characterised by a steep decline from peak viral load during week 12–20 
post-infection to a stabilised viral load set point that has been positively correlated with the rate of disease pro-
gression4,5. This decline and set point maintenance is largely mediated by HIV-1 specific CTL responses. Vertically 
1Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 2KEMRI-Wellcome 
Trust Research Program, Centre for Geographical Medicine Research, Kilifi, Kenya. 3Department of Global 
Health, University of Washington, Seattle, Washington, United States of America. 4Department of Paediatrics 
and Child Health, University of Nairobi, Nairobi, Kenya. 5Department of Medicine, University of Washington, 
Seattle, Washington, United States of America. 6Department of Medicine, University of California San Diego, San 
Diego, California, United States of America. 7Section of Paediatrics, Department of Medicine, Wright Fleming 
Institute, Imperial College London, London, United Kingdom. 8Kenyan Medical Research Institute, Nairobi, 
Kenya. 9Department of Epidemiology, University of Washington, Seattle, Washington, United States of America. 
10Department of Pediatrics, University of Washington, Seattle, Washington, United States of America. 11Department 
of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden. *These authors contributed 
equally to this work. Correspondence and requests for materials should be addressed to M.A.G.K. (email: miguel.
garciaknight@ndm.ox.ac.uk)
Received: 12 May 2016
Accepted: 17 June 2016
Published: 12 July 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:29536 | DOI: 10.1038/srep29536
infected infants experience a higher peak viraemia compared to adults6, a slower decline in viral load over the first 
two years of infection7 and lack a well-defined viral load set point. However, albeit on a lower magnitude com-
pared to adults, vertically infected infants can mount HIV-1 specific CTL responses from birth8–10. This indicates 
that infant HIV-1 specific responses can be functional and select for viral escape variants11,12.
The rate of evolution in HIV-1 is one of the highest in nature, and a striking degree of viral genetic diversity 
is observed within HIV-1-infected individuals13. The error prone nature of the viral reverse transcriptase, a high 
rate of recombination, and a high replicative capacity all contribute to the genetic diversity. This plasticity enables 
viral adaptation to the host immune response14 and the functional efficacy of the CTL response can be observed 
by the selection of viral escape variants and differences in CTL-restricted epitopes15–17. Detailed longitudinal 
characterisation of the HIV-1 specific immune response has shown that CTLs exert a significant selective pressure 
on HIV-1 in early adult infection15,18. However, it is not known to what extent CTL-mediated selection pressure 
drives HIV-1 evolution in early life of infants, and how these functional differences may determine viral control 
and ultimate clinical outcome. Selection pressure such as that imposed by the host CTL response will influence 
the evolutionary rate of HIV-1 and the ratio of nonsynonymous and synonymous substitutions (dN/dS) provides 
a robust measure of both the mode and strength of selection. The intra-host evolutionary dynamics of HIV-1 
and its relationship to clinical outcome has been studied in both adults19–22 and infants23–26, with the majority 
of studies focusing on the envelope gene encoding the primary targets of the humoral immune response27. The 
major targets of the CTL response, however, lie principally in the gag, pol and nef genes. Although the relationship 
between the evolutionary dynamics in these genes and clinical outcomes has been explored to some extent in 
adults28,29, little is known about this relationship during paediatric HIV-1 infection.
In a cohort of perinatally infected Kenyan infants, we estimated joint and individual evolutionary rates and 
selection across gag, pol and nef. We also investigated the influence of the infant CTL response on evolutionary 
parameters. Finally we assessed the association between clinical outcome and selection in CTL epitopes. Our 
results indicate a clear association between stronger immune selection on CTL-restricted epitopes and less severe 
immunosuppression during early infant HIV-1 infection.
Results
Participant characteristics. HIV-1 gag, pol or nef sequences at three or more longitudinal time points were 
recovered from 19 of 23 eligible infants (Table 1). From 83 available specimens sequentially collected during the 
first 24 months of infant HIV-1 infection, sequence recovery was 98% for gag, 64% for pol and 87% for nef. Of the 
19 infants, 13 (68%) were male, 12 (63%) became infected peripartum and seven (37%) became infected in utero. 
The median peak viral load was 7.2 log10 viral RNA copies/mL of plasma (interquartile range [IQR]: 6.6–7.6); the 
median absolute CD4 T cell count and CD4% at 6 months of age were 1415 cells/mL (IQR: 760–2195 cells/mL) 
and 22% (IQR: 16–26%), respectively (S1 Table). As expected, phylogenetic analysis showed clustering of 
sequences sampled longitudinally for the same infant (Fig. S1). The baseline characteristics of the 19 infants were 
representative of infants in the parent cohort (S1 Table). Subtype analysis showed that 11 infants were infected 
with HIV-1 sub-subtype A1 (58%) and one infant with HIV-1 subtype D (5%). This result was concordant in all 
the analysed genetic regions. Seven infants (37%) showed discordant subtype classification between HIV-1 genes 
that was unique from previously described circulating recombinant forms (CRFs), indicating a large proportion 
of unique recombinant forms (URFs, S2 Fig.).
HIV-1 evolutionary rates were highest in nef followed by gag and pol. The average evolution-
ary rates for gag, pol, and nef were 5.9 (95% confidence intervals [CI]: 5.0–7.0), 1.5 (CI: 1.0–2.0) and 12.6 
(CI: 10.0–15.0) nucleotide substitutions/1000 sites/year, respectively. The average evolutionary rates were sig-
nificantly higher in gag and nef compared to pol (P = 0.002 and P < 0.0001, respectively), and in nef compared 
to gag (P = 0.03, Fig. 1A). The patient-specific evolutionary rates across gag and nef did not correlate (ρ = 0.2, 
P = 0.5; Fig. 1B) and across pol it was consistently low between individuals, indicating considerable evolutionary 
constraint. Overall, dN/dS ratios indicated moderate purifying selection across gag and nef (0.7 [CI: 0.5–0.8] and 
0.8 [0.6–0.9], respectively), and strong purifying selection across pol (0.3 [CI: 0.2–0.4]). Individual estimations 
indicated that four (IDs: 170, 211, 291 and 334), zero and one (ID: 211) infants showed overall positive selection 
across gag, pol and nef, respectively.
Evolutionary rate was lower in infants with non-severe immunosuppression than in infants with 
severe immunosuppression across gag and nef. In order to assess associations between clinical out-
comes and evolutionary parameters, infants were stratified into groups based on severe immunosuppression (nadir 
CD4% ≤ 15), peak viral load, mode of transmission, and HIV-1 subtype (Table 2). The evolutionary rate was sig-
nificantly lower in infants with non-severe immunosuppression compared to those with severe immunosuppres-
sion across gag and nef (P = 0.008 and 0.008, respectively; Table 2). In addition, selection was significantly stronger 
in infants with non-severe compared to those with severe immunosuppression across gag (1.4 [CI: 1.1–1.8] 
vs. 0.4 [CI: 0.3–0.5]; P = 0.006). Three of four infants with overall positive selection across gag (IDs: 170, 211 and 334), 
and the single infant with global positive selection across nef (ID: 211) were all infants with non-severe immunosuppres-
sion. No significant difference was observed in median peak viral load between non-severely immunosuppressed and 
severely immunosupressed infants (6.6 vs 7.3 log10 viral RNA copies/mL of plasma, P = 0.2 [Mann-Whitney U test]).
The evolutionary rate in nef was higher in infants with high peak viral loads (above median peak viral load) 
compared to those with low peak viral loads (below median, P = 0.007). The evolutionary rate was also higher in 
nef in infants infected with HIV-1 non-A subtypes compared to those infected with HIV-1 subtype A (P = 0.018). 
Interestingly, five of seven non-subtype A infected infants were infected with URFs, and all these five infants had 
nef sequences that clustered with subtype A-like sequences. No significant differences were observed between 
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evolutionary rate estimates and selection across pol between infant groups (Table 2), or between evolutionary 
parameters in any genetic region in infants stratified by mode of transmission.
CTL targeted regions were under stronger selection than non-CTL targeted regions in gag 
and nef. To investigate the influence of infant CTL responses in early viral evolution, we used infant HLA 
types to partition viral sequences into epitopes putatively restricted by the infant CTL response (CTL+ ) and 
non-restricted parts (CTL− ). Differences in estimates of evolutionary rate and selection strength was assessed 
on both the group level and the individual level. Overall, no significant differences in evolutionary rate between 
CTL+ and CTL− regions was seen across gag and pol. However, on the individual level, three infants (IDs: 261, 
313 and 334) had significantly higher evolutionary rate in CTL+ vs. CTL− regions. (P < 0.05 for all comparisons). 
Overall, the nef gene showed contrasting results with significantly higher evolutionary rate in CTL+ regions 
(18.4 nucleotide substitutions/1000 sites/year [CI: 14.0–24.0]) compared to CTL− regions (9.1 [CI: 7.0–12.0], 
P < 0.001). Individual comparisons indicated faster rates in CTL+ regions in five infants (IDs: 170, 211, 231, 281, 
411 and 454) and slower rates in one infant (ID: 424) compared to CTL− regions (P ≤ 0.05 for all comparisons).
Estimates of selection in partitioned genetic regions indicated that dN/dS ratios in gag were significantly 
higher in CTL+ (1.0 [CI: 0.7–1.4]) vs. CTL− regions (0.5 [CI: 0.4–0.7], P = 0.008). Individual estimates indi-
cated that the same three individuals with faster evolutionary rates in CTL+ vs. CTL− regions, also had signif-
icantly stronger selection in CTL+ vs. CTL− regions (P < 0.05 for all comparisons). Similar results were seen 
in nef with significantly higher dN/dS ratios in CTL+ (1.2 [CI: 0.8–1.6]) vs. CTL− regions (0.5 [CI: 0.4–0.7]; 
P = 0.001) on the group level. Individual estimates indicated that six infants had significantly stronger selection in 
CTL+ vs. CTL− regions (P < 0.05 for all comparisons), four of which (IDs: 170, 211, 231, and 411) were also the 
infants with higher evolutionary rates in CTL+ vs. CTL− regions. No significant differences in selection pressure 
between CTL+ /− regions were observed in pol at either the group level or the individual level.
Infant ID Sex MOT Peak VL*
CD4% 
nadir† (TP)
Age last 
seen, mo
#Of sequences/
TP
HLA A; B; C Subtypegag pol nef
135 M IU 7.65 2 (4) 15 4 0 4 32, 6802; 39, 44; 04, 12 A1
159 F P 6.94 18 (4) 24 6 1 4 29, 30; 4501, 4501; 06, 06 A1
168 M P 8.15 6 (4) 18 6 3 6 24, 29 ;15, 5802; 02, 04 URF
170 M IU 5.94 17 (3) 18 4 4 4 30, 3402; 4201/2, 57; 07, 17 A1
211 M P 7.63 17 (4) 24 6 4 6 30, 6802; 4201/2, 4201/2; 07, 17 URF
231 F P 6.26 18 (4) 24 4 4 4 26, 34; 35, 53; 04, 04 URF
258 M IU 6.68 20 (3) 12 4 4 2 03, 30; 15, 7301;15, 17 A1
259 M P 7.24 34 (4) 24 3 4 3 23, 74; 58, 4501; 07, 07 A1
261 F P 6.57 16 (4) 24 5 3 5 2, 29; 5802, 35; 06, 07 URF
281 M P 6.60 21 (3) 12 4 3 4 23, 74; 15, 15; 02, 02 A1
291 M P 7.23 9 (6) 15 6 4 6 29, 74; 4201/2, 15; 02, 17 A1
303 M P 7.62 17 (4) 12 2 3 1 30, 30; 4501, 4501; 1601, 1601 D
313 M IU 7.45 12 (6) 24 4 2 3 33, 6802; 15, 35; 03, 04 URF
334 F P 6.46 24 (4) 9 4 0 4 29, 26/66; 13, 15; 02, 06 A1
411 F P 7.15 15 (5) 24 4 4 4 30, 30; 15, 42; 14, 17 A1
424 F IU 7.45 7 (2) 6 3 2 3 02, 6802; 51, 08; 07, 1601 URF
440 M IU 6.88 10 (3) 10 4 1 3 02, 30; 4501/03, 4902; 06, 1601 A1
454 M P 7.64 23 (5) 24 4 4 4 02, 31; 08, 15; 07, 08 URF
485 M IU 6.39 4 (7) 24 4 3 2 NA; NA; NA A1
Table 1.  Infant characteristics. * Maximum VL measurement within 6 months of infection, log10 HIV-1 
plasma RNA copies/mL of plasma. †Within 15 months of age. TP, time points; NA, not available; VL, viral load; 
mo, months; MOT, mode of transmission; IU, in utero; P, peripartum; URF, unique recombinant form, parental 
subtypes shown in S3 Table.
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CTL targeted regions across gag and nef were under stronger selection in infants with 
non-severe immunosuppression in contrast to infants with severe immunosuppression. 
To further explore the relationship between CTL-mediated selection in gag and nef and the clinical outcome of 
infection, we estimated differences in dN/dS ratios in CTL+ /− regions in infant groups stratified by the severity 
of immunosuppression. The pol region was not considered due to the consistently low variation and evolutionary 
signal. The dN/dS ratios were higher in CTL+ vs. CTL− regions in infants with non-severe immunosuppres-
sion in both gag (2.3 [CI: 1.6–3.3] vs. 1.0 [CI: 0.7–1.5], P = 0.006) and nef (2.6 [CI: 1.7–3.8] vs. 0.5 [CI: 0.2–0.8], 
P < 0.001; Table 3). No significant differences were found between dN/dS ratios across CTL+ and CTL− regions 
in infants with severe immunosuppression in either gag or nef.
Discussion
The positive correlation between HIV-1 evolutionary rate and disease progression rate has been demonstrated 
several times in adults20,22,30. Here, we show that this is true in infant HIV-1 infection as well. We also demonstrate 
a clear association between stronger immune selection on CTL-restricted epitopes and less severe immunosup-
pression during early infant HIV-1 infection. However, in contrast to adults, evidence of CTL-mediated selection 
is only seen in a minority of vertically-infected infants who maintain relatively high CD4 percentages. Our results 
support the notion that infant CTL responses may have the functional capacity to exert selective pressure on cog-
nate epitopes, and that possession of functional CTL responses is associated with favourable clinical outcomes. The 
strengths of our study approach include the use of historical samples obtained before the era of infant ART, a clin-
ically well characterised cohort, a relatively large sample size which enabled stratification of individuals according 
to clinical parameters, and the analysis of longitudinal changes in viral sequence in early infant HIV-1 infection.
The few studies that have addressed the association between CTL-mediated evolution and differential clini-
cal outcomes in infant HIV-1 infection have reported divergent findings. Recently, Adland et al.31 indicated that 
HLA played a limited role in protection from HIV-1 disease progression in children compared to adults, with 
modest associations between the presence of a protective HLA allele and disease severity in children or with 
in vitro viral replicative capacity of patient derived chimeric viruses. In addition, no evidence of de novo CTL 
escape was seen in viral sequences from severely immunosuppressed infants (CD4% < 20 within the first year 
of life) bearing protective HLA B alleles. Our data indicate that CTL-mediated selection indeed can occur as a 
consequence of the infant CTL response and that this is associated with non-severe immunosuppression. This 
suggests a possible protective role for HLA in mediating HIV-1 disease outcomes in early infection following 
vertical transmission, in some but not all infants, potentially explaining the inconsistent findings in previous 
reports. Our results are in accordance with a study of five infants with no evidence of severe immune suppres-
sion (based on the CDC paediatric HIV-1 classification), which reported global positive selection in nef and 
CD8 T cell driven mutations in HLA A* 24-restricted nef epitopes over the first year of life11. Similarly, amino 
acid changes in CTL-associated nef epitopes was reported for children with non-progression but not for chil-
dren with disease progression32. As discussed by Adland et al.33, further evidence of functional immune driven 
selection in neonatal HIV-1 infection comes from observations that replicative capacity of infant Gag-Protease 
chimeric viruses was significantly reduced compared with matched maternal chimeric viruses34. Our data sug-
gest that within the first year of life, a proportion of infants may select viral variants that harbour CTL-driven 
mutations. Further studies are needed to determine associations between CTL-driven mutations, fitness costs 
and viral load dynamics in early infant infection.
Figure 1. Evolutionary rates across HIV-1 gag, pol and nef genes from infants sampled under 2 years 
of age. (A) Summary of nucleotide substitution rates across gag, pol and nef with median (line) 1st and 
3rd quartiles (box) and the 10th and 90th percentile (whiskers) shown. The Mann Whitney U test was used 
to assess differences between groups. (B) Rank-based Spearman correlations between the nucleotide 
substitution rate across gag and nef.
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Despite the apparent association between CTL-driven selection in HIV-1 genes and clinical outcome in this 
study, uncontrolled viremia was observed throughout the first two years of life in the majority of infants. Some 
of the unique features of paediatric immunity may account for this discrepancy, particularly with regards to 
the increased CD4 T cell counts that are seen in infancy both in the periphery and in mucosa when compared 
to adulthood. Although naïve (CCR5−) CD4 T cells predominate in the periphery, evidence from the rhesus 
macaque model indicate that the pool of activated and proliferating CD4+ targets is greatly increased in neonatal 
tissues compared to adults (10-fold in the gut), and that these cells are preferentially targeted and depleted by 
simian immunodeficiency virus35,36. The abundance37 and profound loss of CCR5+ CD4 coupled with the high 
rate of thymic turnover during infancy, may supply HIV-1 with a virtually unlimited supply of susceptible target 
cells. As a consequence, functional infant CTL responses may not reflect the dynamics of peripheral blood virae-
mia in early life because these are masked by rapid viral turnover in the context of overabundance of susceptible 
target cells. Notwithstanding, we observed a large effect size of the median difference between peak viral loads in 
non-severely immunosuppressed  vs severely immunosuppressed  groups that did not reach significance, likely 
due to a power effect. This suggests a relationship between infant pathogenesis, peak viral load and evolutionary 
dynamics that merit further studies.
Due to the use of viral population sequences, our estimates of evolutionary rate across gag, pol and nef prob-
ably provide a lower bound on this parameter17. Our estimates ranged from 10−2 nucleotide substitutions/site/
year in nef, to 10−3 nucleotide substitutions/site/year in gag and pol which is in accordance with rates estimated 
during adult infection27,38, although direct comparisons with previous reports may be difficult to interpret due 
to methodological differences. Our analysis was adapted from Hightower et al. who reported an average rate of 
0.72 nucleotide substitutions/1000 sites/year across pol during adult chronic HIV-1 subtype B infection17. Our 
estimate of 1.5 nucleotide substitutions/1000 sites/year in pol is approximately twice as high and could reflect 
differences in evolutionary rate between early and chronic infection19 or differences between adult and infant 
infection (e.g. higher viral loads in infants that may influence evolutionary rates). However, the low evolutionary 
rate across pol relative to gag and nef suggests considerable evolutionary constraints in this region, as would be 
expected from genes encoding enzymes with critical functions in the viral replication cycle.
In accordance with previous estimates27, nef was shown to evolve at the highest rate, a reflection of the molec-
ular plasticity of its encoded protein that is involved in diverse roles during viral replication and pathogenesis. In 
addition, the influence of CTL selection was most apparent in nef as a) six infants showed significantly stronger 
selection in CTL+ vs. CTL− regions compared to three across gag, and b) the overall association between CTL 
Gene
Immunosuppression Peak VL Mode of transmission HIV subtype
NSIS SIS P (LRT) < Median > Median P (LRT) in utero peripartum P (LRT) A1 Other P (LRT)
N = 10 N = 8 N = 9 N = 9 N = 7 N = 11 N = 11 N = 7
gag †rate, 
(95% CI)
4.2 
(3.0–5.0)
8.8  
(7.0–11.0) 0.008 (19.6) 6.1 (5.0–7.0) 5.8 (5.0–7.0) 0.8 (0.07)
6.7 
(5.0–9.0) 5.7 (5.0–7.0) 0.4 (0.8)
6.0 
(5.0–7.0)
5.9 
(5.0–8.0) 1.0 (0.0)
gag dN/dS, 
(95% CI)
1.4 
(1.1–1.8)
0.4 
(0.3–0.5) 0.006 (10.4) 0.9 (0.7–1.2) 0.5 (0.4–0.7) 0.08 (3.0)
0.4 
(0.3–0.6) 0.8 (0.6–1.0) 0.1 (2.4)
0.7 
(0.5–0.8)
0.6 
(0.5–0.9) 0.8 (0.05)
N = 9 N = 4 N = 9 N = 4 N = 3 N = 10 N = 7 N = 6
 pol rate 
(95% CI)
1.4 
(1.0–2.0)
2.1 
(1.0–3.0) 0.2 (1.8) 1.4 (1.0–2.0) 1.6 (1.0–2.0) 0.7 (0.2)
1.0 
(0.0–2.0) 1.6 (1.0–2.0) 0.3 (0.9)
1.5 
(1.0–2.0)
1.6 
(1.0–2.0) 0.9 (0.02)
pol dN/dS 
(95% CI)
0.3 
(0.2–0.5)
0.3 
(0.1–0.5) 1.0 (0.00) 0.2 (0.1–0.4) 0.4 (0.2–0.6) 0.3 (1.2)
1.1 
(0.2–2.8) 0.2 (0.1–0.4) 0.2 (1.9)
0.4 
(0.2–0.7)
0.2 
(0.09–0.4) 0.2 (1.4)
N = 9 N = 7 N = 7 N = 9 N = 5 N = 11 N = 9 N = 7
nef rate, 
(95% CI)
8.0 
(6.0–11)
19.4 
(15.0–25.0) 0.008 (20.2)
6.7 
(4.0–10.0)
16.6 
(13.0–20.0) 0.007 (17.3)
14.1 
(9.0–20.0)
12.1 
(10.0–15.0) 0.5 (0.5)
9.0 
(6.0–12.0)
16.1 
(13.0–20.0) 0.018 (8.74)
nef dN/dS, 
(95% CI)
1.1 
(0.8–1.5)
0.6 
(0.4–0.8) 0.2 (1.8)
0.7 (0.4– 
1.2) 0.8 (0.6–1.0) 1.0 (0.00)
0.4 
(2.0–0.6) 1.0 (0.8–1.3) 0.03(4.9)
0.8 
(0.5–1.1)
0.8 
(0.6–1.0) 1.0 (0.0)
Table 2.  Global evolutionary rates and dN/dS rate ratios in infants stratified by clinical parameters. * Median 
of N = 19 infants. †Rate = nucleotide substitutions/1000 sites/year. NSIS, non-severely immunosuppressed (CD4% 
> 15 during follow-up). SIS, severely immunosuppressed (CD4% ≤ 15 during follow-up). VL, viral load; LRT, 
likelihood ratio test. Bold indicates significant values after correction for multiple comparisons.
Gene Parameter
dN/dS ratio (95% CI)
CTL+ CTL− P LRT
gag
NSIS (N = 10) 2.3 (1.6–3.3) 1.0 (0.7–1.5) 0.006 7.6
SIS (* N = 7) 0.5 (0.3–0.8) 0.4 (0.3–0.5) 0.717 0.1
nef
NSIS (N = 9) 2.6 (1.7–3.8) 0.5 (0.2–0.8) <0.001 20.4
SIS (N = 7) 0.7 (0.4–1.1) 0.6 (0.4–0.8) 0.525 0.4
Table 3.  dN/dS rate ratios across gag and nef in HLA and non-HLA targeted epitopes in infants stratified 
by immunosuppression. SIS, severely immunosuppressed; NSIS, non-severely immunosuppressed; LRT, 
likelihood ratio test. * HLA data missing from infant 485.
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selection and favourable clinical outcome resulted in higher LRT scores in nef compared to gag. This observa-
tion probably reflects the early targeting of nef by CTL responses as seen in both adult HIV-1 infection and in 
SIV infection. Comparably, CTL targeting of gag epitopes has been shown to occur at a later stage of infection. 
Alternatively, these observed differences may reflect strong protective effects of CTL selection in nef during acute 
HIV-1 infection.
We also found a lower evolutionary rate in nef among HIV-1 subtype A compared with non-subtype A 
infected infants. This result together with the higher viral evolutionary rate seen in infants with severe immuno-
suppression are in line with previous studies on adults that show a positive correlation between rate of evolution 
and disease progression20,22,30 and a slower disease progression in HIV-1 subtype A-infected adults compared 
with other HIV-1 subtypes and CRFs39,40. These results warrants further studies on HIV-1 strain-specific effects 
on disease progression among both infants and adults.
In summary, we find that infant CTLs exert significantly stronger selection across gag and nef epitopes in early 
infection. In addition, we find that stronger selection across CTL epitopes is associated with favourable clinical 
outcomes. These results highlight the potential functionality of infant CTLs despite a lack of viral control with 
implications for the development of protective paediatric HIV-1 vaccines.
Methods
Cohort characteristics, sampling and ethics. Samples were collected, as part of the CTLs and the 
Prevention of HIV-1 Transmission Study, in Nairobi, Kenya between 1999 and 200241. As described in detail 
elsewhere41, the parent cohort consisted of 465 HIV-1-infected women recruited during pregnancy and followed 
for up to two years postpartum with their infants. Mothers were provided with short-course zidovudine (ZDV) 
during the final trimester of pregnancy to reduce the risk of HIV-1 transmission according to contemporaneous 
guidelines42.In the absence of a national ART programme for children, all infants were treatment-naïve during 
the study period. Maternal and infant CD4 T cell counts and RNA viral loads were serially assessed at birth, and 
months 1, 3, 6, 12, 15, 18, 21, and 24. Infant viral loads were measured from cryopreserved plasma specimens, 
using the Gen-Probe assay43 (limit of detection of 50 copies/ml). Infant HIV-1 infection was defined as the first 
detection of HIV-1-gag DNA by PCR from dried blood spots44 or HIV-1 RNA from plasma43. Infection and clas-
sification into in utero, peripartum/early breast milk, or late breast milk transmission were defined as previously 
described41. Ninety transmission events were detected, with timing of infection available for 87 infants. Infant 
HLA types to two digit resolution were determined as previously described45. For evolutionary analyses, infants 
were selected if they were infected by one month of age and if they had three of more longitudinal plasma speci-
mens available for study. Seventy two infants were infected by one month of age and 23 infants had samples from 
three or more longitudinal time points totalling 89 plasma specimens.
Ethics statement. This study was conducted according to the principles expressed in the Declaration of 
Helsinki and the study protocol was approved by the Kenyatta National Hospital Ethics Review Committee 
and the Institutional Review Board of the University of Washington. HIV-1 seropositive pregnant women were 
enrolled after provision of written informed consent as detailed previously41.
HIV-1 amplification and sequencing. As detailed in the Supplementary methods, viral RNA was isolated 
from cryopreserved plasma samples and purified using the QIAamp Viral RNA extraction kit (Qiagen, Limburg, 
Netherlands) followed by reverse transcription and nested PCR (Table S2) for gag, pol and nef. Amplified DNA was 
purified and sequenced on a 48 capillary ABI-3730 DNA analyser using Applied Biosystems BigDye Terminator 
v3.1 (Waltham, MA, USA) chemistry. Contigs were assembled and open reading frames edited using Geneious 
v6.1.646 (Biomatters Ltd.). Full length gag and nef sequences corresponding to HXB2 nucleotide positions 790–
2289 and 8797–9414, respectively, were obtained (except for gag sequences from infant 313, HXB2 positions 
880–2289) as well as near full length pol sequences (2.0–2.8 kb spanning the protease through to integrase cod-
ing sequences, HXB2 positions 2358–5096). Ambiguous bases were identified using the Find Heterozygotes tool 
packaged in Geneious v6.1.6 and defined as peaks with quality scores > 10 with a secondary peak height above 
25% of the maximal peak. GenBank accession numbers for the sequences are indicated in Table S4.
HIV-1 subtyping. The earliest infant sample following infection was used for subtyping and gag, pol and 
nef, sequences were analysed separately. Pairwise alignments of infant samples were made using the version 
and settings of MUSCLE47 packaged in Geneious v6.1.6. Profile alignments of infant sequences and the Los 
Alamos National Library HIV sequence database subtype reference alignment (2010)48 were made in Clustal 
X249. All alignments were manually inspected and edited in MEGA v5.250. Maximum-likelihood phyloge-
netic reconstruction (GTR + γ + I) with branch support estimated by the Approximate Likelihood Ratio Test 
(aLRT)-Shimodaira-Hasegawa-like (SH) procedure51 in PhyML 3.0 was carried out. Branches with aLRT-SH 
values above 0.85 were considered as statistically well supported. Sequences that either clustered with a known 
circulating recombinant form (CRF), clustered within different subtypes in distinct genetic regions, showed inter-
mediate clustering across distinct genetic regions or presented long branches within a cluster were analysed as 
recombinant subtypes. Characterisation, using Simplot and Bootscan analysis in Simplot v3.5.152, was carried out 
as detailed in the Supplementary methods.
Phylogenetic estimation of intra-patient rates of evolution in gag, pol and nef. We estimated 
evolutionary rates separately for each individual infant using a maximum likelihood (ML) approach imple-
mented in the HyPhy package53 with suitable modifications needed to analyse gag, pol and nef, respectively17,54. 
The Tamura-Nei (TN93) model of nucleotide evolution and a strict molecular clock were used to estimate 
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evolutionary rates based on the procedure described by Hightower et al.17, having determined that rate estimates 
in all genes were unaffected by the complexity of the evolutionary model (Fig. S4). Briefly, sequences from each 
individual were aligned, and equipped with a “linear” tree, where the sequence at the oldest time point as the root, 
the second oldest sequence as the direct descendant of the root, and so on. Sequences from all individuals were 
analysed both individually (one individual at a time), and jointly (all individuals together) by profile likelihood in 
the ML phylogenetic framework. The likelihood ratio test (LRT) was used to test for deviations from molecular 
clock in a given individual, assuming the χ 2N−2 asymptotic distribution of the test statistic (N = number of time 
points). Estimates of codon substitution rates, and the dN/dS ratio were obtained using the Muse-Gaut 94 x REV 
(MG94) codon-based model of evolution55. Infant HLA types at two-digit resolution and the 2013 LANLDB 
annotation of CTL-restricted epitopes56 were used to partition gag, pol and nef sequences into regions restricted 
by infant CTL and those that were not. The software pipeline implementing the analysis can be downloaded from 
https://github.com/spond/PolEvolution.
Data analysis. Comparisons of global ML estimates of the evolutionary rates between HIV-1 genes were car-
ried out using the Mann-Whitney U test. Two-sided p-values were calculated for analysis and values of p < 0.05 
were considered significant. Correlations were tested using the Spearman’s rank correlation coefficient. Statistical 
analysis and plots were made in GraphPad Prism version 6.0 (GraphPad Software inc.). Severe immunosuppres-
sion was defined as a nadir CD4% ≤ 15 at any time point up to 15 months of age due to the association with infant 
mortality within 2 years of life in this cohort57. The Holm-Ŝidák test was used to correct for multiple comparisons.
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